Drug Profile
Research programme: anticancer therapeutics - AstraZeneca/PTC Therapeutics
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator AstraZeneca; PTC Therapeutics
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in England
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in USA
- 29 Jun 2011 Early research in Cancer in England (unspecified route)